Skip to search formSkip to main contentSkip to account menu

Recurrent Chronic Lymphoid Leukemia

Known as: CLL, relapsed, Recurrent Chronic Lymphocytic Leukemia, chronic lymphocytic leukemia, relapsed 
The reemergence of chronic lymphocytic leukemia after a period of remission.
National Institutes of Health

Related topics

Related topics

27 relations
Atypical lymphocyteB lymphoblastB-LymphocytesBCL3 gene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab… 
Highly Cited
2017
Highly Cited
2017
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Chronic lymphocytic leukemia (CLL) patients progressed early on ibrutinib often develop Richter transformation (RT) with a short… 
Highly Cited
2017
Highly Cited
2017
Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.
To the editor: Over the past 4 decades, outcomes have improved dramatically among pediatric patients with acute lymphoblastic… 
Highly Cited
2016
Highly Cited
2016
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.
Although agents targeting B-cell receptor signaling have provided practice-changing results in relapsed chronic lymphocytic… 
Highly Cited
2014
Highly Cited
2014
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
BACKGROUND Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical… 
Highly Cited
2012
Highly Cited
2012
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
Abstract Lucatumumab is a fully humanized anti-CD40 antibody that blocks interaction of CD40L with CD40 and also mediates… 
Highly Cited
2011
Highly Cited
2011
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Patients with relapsed chronic lymphocytic leukemia (CLL) and high-risk features, such as fludarabine refractoriness, complex… 
Highly Cited
2009
Highly Cited
2009
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
PURPOSE Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features achieve poor outcomes with traditional… 
Highly Cited
2009
Highly Cited
2009
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
In chronic lymphocytic leukemia (CLL) lenalidomide causes striking immune activation, possibly leading to clearance of tumor… 
Highly Cited
2007
Highly Cited
2007
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
Chronic lymphocytic leukemia (CLL) patients with aggressive molecular characteristics such as deletion of 17p13.1 do not respond… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)